Free Trial
NASDAQ:CGEM

Cullinan Therapeutics Q2 2024 Earnings Report

Cullinan Therapeutics logo
$7.54 -0.07 (-0.92%)
Closing price 04:00 PM Eastern
Extended Trading
$7.54 0.00 (-0.07%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cullinan Therapeutics EPS Results

Actual EPS
-$0.75
Consensus EPS
-$0.73
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Cullinan Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cullinan Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
7:15AM ET

Upcoming Earnings

Cullinan Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Friday, November 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cullinan Therapeutics Earnings Headlines

Research Analysts Issue Forecasts for CGEM Q3 Earnings
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
Cullinan Therapeutics: Q2 Earnings Snapshot
See More Cullinan Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cullinan Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cullinan Therapeutics and other key companies, straight to your email.

About Cullinan Therapeutics

Cullinan Therapeutics (NASDAQ:CGEM), a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

View Cullinan Therapeutics Profile

More Earnings Resources from MarketBeat